1 / 23

Tuberculosis in Children: Treatment and Monitoring

Module 10B - March 2010. Tuberculosis in Children: Treatment and Monitoring. Project Partners. Funded by the Health Resources and Services Administration (HRSA). Module Overview. Treating childhood TB Monitoring the pediatric patient on TB treatment. Learning Objective.

sylvia
Download Presentation

Tuberculosis in Children: Treatment and Monitoring

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Module 10B - March 2010 Tuberculosis in Children: Treatment and Monitoring

  2. Project Partners Funded by the Health Resources and Services Administration (HRSA)

  3. Module Overview • Treating childhood TB • Monitoring the pediatric patient on TB treatment

  4. Learning Objective Upon completion of this session, participants will be able to: • Determine the appropriate treatment regimen for a child with tuberculosis • State the circumstances under which corticosteroids should be added to the regimen • Name the essential monitoring that should occur when a child is under treatment for tuberculosis

  5. Treating Childhood TB

  6. Treating Childhood TB • Treatment regimens for children are based on prior treatment history and clinical presentation • Most children with TB have uncomplicated (smear-negative) pulmonary/intrathoracic TB or non-severe forms of EPTB • The principles for TB treatment in the HIV-infected child are the same as in the HIV-uninfected child

  7. Treating Childhood TB (2) • WHO has updated dosage recommendations for children based on pharmacokinetic studies and expert consultation • Weight should be monitored throughout treatment and dose adjusted for weight increases • Pediatric intermittent dosing recommendations are under review • Ethambutol and streptomycin are the only drugs with approved pediatric thrice weekly dosing

  8. Pediatric Dosing Table

  9. Recommended Regimens H= isoniazid; R= rifampicin; Z= pyrazinamide; E= ethambutol; PTB= pulmonary TB; EPTB= extra-pulmonary TB; HIV= human immunodeficiency virus

  10. Recommended Regimens (2) H= isoniazid; R= rifampicin; Z= pyrazinamide; E= ethambutol; S= streptomycin; PTB= pulmonary TB; EPTB= extra-pulmonary TB; MDR-TB= multidrug resistant tuberculosis

  11. Treating TB Meningitis H = isoniazid; R = rifampicin; Z = pyrazinamide; S = streptomycin; Eth = ethionamide; WHO = World Health Organization

  12. Use of Corticosteroids • Recommended in all cases of TB meningitis • Dosage= 2mg/kg daily x 4 weeks then gradually reduced (tapered) over 1-2 weeks • Corticosteroids may be used for the management of other complicated forms of TB such as: • Complications of airway obstruction from lymphatic TB • TB pericarditis

  13. Monitoring the Pediatric Patient on TB Treatment

  14. Monitoring Challenges • Bacteriological monitoring of treatment response is not practical in most children • Monitoring for toxicity is more difficult • Need to find ways to get the child to take the treatment as the taste is often not pleasant to the child

  15. Dosing Tips • Anticipate a trial-and-error period at start • Layer vehicle and drug on a spoon • Possible vehicles to hide drug in: • syrup, chili, jam, baby food, pudding, etc. • Teach child to take contents of spoon without chewing • Follow medication with a liquid or other food the child likes to clear palate • Be prepared to try new methods or incentives • Never let the child think the dose is optional

  16. Treatment Adherence • Educate about TB and the importance of completing treatment • Encourage and support the child, parent(s) and immediate family • Observe administration of treatment (DOT)

  17. Treatment Adherence (2) • All children should receive treatment free of charge, whether or not the child is smear-positive at diagnosis • When they become available, pediatric fixed-dose combinations should be used whenever possible to improve simplicity and adherence • Patient treatment cards are recommended for documenting treatment adherence

  18. Hospitalization • Children with severe forms of TB should be hospitalized for intensive management where possible • Conditions that merit hospitalization include: • TB meningitis and miliary TB, preferably for the first 2 months • Any child with respiratory distress • Spinal TB • Severe adverse events, such as clinical signs of hepatotoxicity (e.g., jaundice)

  19. Monitoring Throughout Treatment • Ideally, each child should be assessed by the National Tuberculosis Program (NTP) (or those designated by the NTP to provide treatment) at least at the following intervals: • 2 weeks after treatment initiation • Monthly until end of the intensive phase • Every 2 months until treatment completion

  20. Monitoring Throughout Treatment (2) • The assessment should include, at a minimum: • Review of symptoms • Review of adherence • Enquiry about any adverse events • Weight measurement • Review of the patient treatment card • Follow-up sputum for AFB smear microscopy, especially at 2 months for any child who was sputum smear-positive at diagnosis

  21. Monitoring Throughout Treatment (3) • The NTP is responsible for organizing treatment in line with the Stop TB Strategy, and ensuring the recording and reporting of cases and their outcomes • Good communication is necessary between the NTP and clinicians treating children with TB • Adverse events noted by clinicians should be reported to the NTP

  22. Immune Reconstitution • This temporary exacerbation of symptoms, signs, or radiographic manifestations sometimes occurs after beginning anti-TB treatment • Can simulate worsening disease with fever and increased size of lymph nodes or tuberculomas • Can be brought about by improved nutritional status or by the anti-TB treatment itself • Can occur after initiation of antiretroviral therapy (ART) in HIV-infected children with TB, and is known as the immune reconstitution inflammatory syndrome (IRIS)

  23. Summary • Treatment regimens for children are based on prior treatment history and clinical presentation • Pediatric dosages for the first-line anti-TB drugs have changed based on new pharmacokinetic evidence • Use of pediatric FDC formulations when available along with other treatment adherence strategies should be used to simplify standard regimen administration and improve adherence • Regular monitoring throughout treatment should occur as described to ensure clinical improvement and adherence

More Related